<DOC>
	<DOCNO>NCT00558298</DOCNO>
	<brief_summary>The purpose study document long-term safety 25 , 50 75 mg long-acting injectable risperidone give via injection gluteal muscle every 2 week patient schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>A Long Term Study Safety Long Acting Injectable Risperidone Patients With Schizophrenia Schizoaffective Disorder .</brief_title>
	<detailed_description>Noncompliance take medication common among people schizophrenia , frequent cause relapse symptom . A long-acting injectable formulation ensure slow steady release risperidone period several week would eliminate need take medication daily basis , improve compliance . This open-label , international , multicenter study patient schizophrenia schizoaffective disorder either complete study RIS-INT-57 RIS-INT-61 drop RIS-INT-61 completion 3 injection cycle . Patients begin study within 7 day final endpoint visit RIS-INT-57 RIS-INT-61 study . The endpoint visit RIS-INT-57 RIS-INT-61 serf first visit ( Visit 1 ) RIS-INT-63 , consider baseline extension study . Patients complete RIS-INT-57 continue receive dose long-acting injectable risperidone ( 25 , 50 75 mg ) receive last 3 month study . Patients complete drop RIS-INT-61 continue receive equivalent dose long-acting injectable risperidone receive study . The blind broken patient RIS-INT-61 study , therefore continue receive double-blind oral medication first 3 week extension study . The total study duration plan least 1 year . The study hypothesis treatment long-acting injectable formulation risperidone every 2 week least 1 year safe well tolerate , assessed adverse event reporting , extrapyramidal symptom rating scale , laboratory test , vital sign measurement , physical examination , body weight measurement , electrocardiogram , injection site evaluation . Patients receive injection risperidone depot microspheres ( 25 , 50 75 mg ) muscle 2-weekly interval least 1 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia ( patient RISINT57 RISINT61 ) schizoaffective disorder ( patient RISINT57 ) accord DSMIV criterion patient complete RISINT57 RISINT61 drop completion 3 injection cycle RISINT61 ( i.e. , Visit 4 ) Patient otherwise healthy basis prestudy physical examination medical history . No DSMIV diagnosis substance abuse dependence within 3 month prior entry RISINT57 RISINT61 ( exclude nicotine caffeine dependence ) No pregnant breastfeed woman No female patient childbearing potential without adequate contraception No history severe drug allergy hypersensitivity No patient know unresponsive risperidone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>risperidone</keyword>
	<keyword>intramuscular injection</keyword>
	<keyword>long-acting injectable</keyword>
</DOC>